Doctor Pezad, Scott William A, Tindel Kaitlin, Nguyen Hoang H
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Pharmacy, Dallas Children's Medical Center, Dallas, TX 75235, USA.
Cardiol Res. 2022 Aug;13(4):242-245. doi: 10.14740/cr1392. Epub 2022 Aug 15.
Ivabradine is currently approved to reduce heart rate in children with chronic heart failure and dilated cardiomyopathy. Ivabradine has also been used off-label in children to treat automatic tachyarrhythmias such as ectopic atrial tachycardia and junctional ectopic tachycardia. Adverse effects of ivabradine at physiological doses as well as its toxicity at supra-physiological doses have rarely been reported in adults. In children, weight-based dosing requires dilution of commercially available ivabradine oral solution for accuracy. We describe a case of ivabradine overdose in a newborn (treated for ectopic atrial tachycardia) secondary to inaccurate dosing leading to the infant receiving 10 times more drug than prescribed. This case highlights potential pitfalls of ivabradine prescription and preparation in children.
伊伐布雷定目前已被批准用于降低慢性心力衰竭和扩张型心肌病患儿的心率。伊伐布雷定也被超适应证用于治疗儿童的自律性快速心律失常,如房性异位性心动过速和交界性异位性心动过速。伊伐布雷定在生理剂量下的不良反应及其超生理剂量下的毒性在成人中鲜有报道。在儿童中,基于体重的给药需要稀释市售的伊伐布雷定口服溶液以确保准确性。我们描述了一例新生儿(因房性异位性心动过速接受治疗)伊伐布雷定过量的病例,原因是给药不准确,导致婴儿接受的药物剂量比处方剂量多10倍。该病例凸显了儿童伊伐布雷定处方和制剂使用中存在的潜在问题。